Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determining the Optimal Hepatitis B Surface Antigen Level for Treatment Cessation of Nucleoside Analogue Therapy in Chronic Hepatitis B: a Prospective Study

NCT02738554 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT02738554
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02738554 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determining the Optimal Hepatitis B Surface Antigen Level for Treatment Cessation of Nucleoside Analogue Therapy in Chronic Hepatitis B: a Prospective Study
Lead sponsor
The University of Hong Kong
Phase
Not applicable
Overall status
Completed
Start date
January 31, 2016
Completion date
January 31, 2020
Enrollment
124 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b